What Is Menopause?
Menopause marks the permanent end of menstruation and fertility. It is defined clinically as 12 consecutive months without a period, in the absence of other causes such as illness or pregnancy. The average age in Australia is 51–52 years, though the normal range spans from the mid-40s to mid-50s. Menopause before age 40 is termed premature ovarian insufficiency (POI) and warrants specialist review.
The term “menopause” is commonly used to describe both the transition period and the years that follow, but clinicians distinguish three phases:
- Perimenopause — the transition, typically 2–8 years, during which cycles become irregular and symptoms emerge
- Menopause — the single point (confirmed after 12 months without a period)
- Postmenopause — the years following menopause
Key Points
- Most women experience menopause between ages 45 and 55; the average in Australia is 51–52.
- Perimenopause — not menopause itself — is when most symptoms first appear, sometimes years before periods stop.
- Vasomotor symptoms (hot flushes, night sweats) affect around 75% of women and on average last 7 years.
- Bone loss accelerates markedly during the perimenopause and early postmenopause.
- Genitourinary symptoms (vaginal dryness, discomfort) worsen over time if untreated; effective treatments exist.
- Hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for most healthy women under 60 or within 10 years of menopause.
- Postmenopausal bleeding always requires prompt medical evaluation.
The Hormonal Transition
The ovaries contain a finite supply of follicles. As this reserve diminishes in the 40s, oestrogen and progesterone production becomes erratic and eventually falls. In perimenopause, oestrogen levels are not simply declining — they are fluctuating unpredictably, swinging between abnormally high and low levels before settling into the consistently low postmenopausal state.
This hormonal volatility is what drives many perimenopausal symptoms. In postmenopause, oestrogen levels stabilise at a new, much lower baseline. Androgens (testosterone, DHEA) also decline gradually, though more slowly.
Symptoms
Vasomotor Symptoms
Hot flushes and night sweats affect roughly 75% of women during the menopausal transition. A hot flush is a sudden sensation of heat, usually spreading from the chest to the neck and face, often with visible flushing and sweating. Night sweats are nocturnal hot flushes that disrupt sleep. Episodes typically last 2–4 minutes. Severity ranges from mildly inconvenient to severely disruptive of work and relationships.
On average, vasomotor symptoms last 7 years, though duration is highly variable. They tend to be most frequent in the first 2 years after the final period, and may begin in perimenopause before periods have stopped.
Sleep Disruption
Poor sleep is one of the most common and debilitating menopausal complaints. Night sweats are a major contributor, but oestrogen decline also directly affects sleep architecture — reducing slow-wave sleep and increasing fragmentation. Secondary insomnia from anxiety or low mood compounds the problem. Addressing vasomotor symptoms often improves sleep; cognitive behavioural therapy for insomnia (CBT-I) has strong evidence as a standalone intervention.
Mood and Cognitive Changes
- Mood lability — irritability, anxiety, or low mood — is common in perimenopause, driven by hormonal fluctuations
- Cognitive symptoms — “brain fog,” reduced concentration, word-finding difficulties — are frequently reported, particularly in late perimenopause and early postmenopause; most resolve over time
- Depression vulnerability — the perimenopause represents a genuine window of increased risk, particularly in women with prior mood disorders
Mood and cognitive symptoms often improve as hormones stabilise in postmenopause. Persistent or severe symptoms should be assessed clinically.
Genitourinary Symptoms (GSM)
The genitourinary syndrome of menopause (GSM) encompasses:
- Vaginal dryness and irritation — from thinning of vaginal mucosa
- Dyspareunia — pain during intercourse
- Recurrent urinary tract infections
- Urinary urgency and frequency
Unlike vasomotor symptoms, which tend to improve over time, GSM typically worsens without treatment. It affects an estimated 40–60% of postmenopausal women but is significantly undertreated because many women do not raise it with their doctors. Effective treatments exist.
Bone Health
The accelerated phase of bone loss begins 2–3 years before the final period and continues for 5–7 years after. Women can lose 10–20% of bone mineral density during this window. This is the mechanism behind the disproportionate rate of osteoporosis in postmenopausal women. Calcium intake, vitamin D sufficiency, weight-bearing exercise, and — where appropriate — hormone therapy or targeted bone-protective treatments are all relevant.
Cardiovascular Changes
Oestrogen has multiple vasculoprotective effects: it helps maintain arterial elasticity, favourably modifies lipid profiles, and supports healthy endothelial function. At menopause:
- LDL cholesterol typically rises
- HDL cholesterol may fall
- Blood pressure tends to increase
- Visceral fat accumulation accelerates
These changes contribute to a narrowing of the cardiovascular risk gap between women and men. Proactive cardiovascular risk monitoring from midlife is warranted.
Diagnosis
Menopause is a clinical diagnosis in women over 45 who have had 12 months of amenorrhoea in the absence of other causes. Blood tests (FSH, oestradiol) are not needed for diagnosis in this age group — results can be misleading due to hormonal fluctuations during perimenopause.
Blood tests may be useful:
- In women under 45 to investigate premature ovarian insufficiency
- When the clinical picture is unclear (e.g., hysterectomy, hormonal contraception masking cycles)
- To guide hormone therapy prescribing in some circumstances
Treatment Options
Hormone Therapy (HRT / MHT)
Hormone therapy — also called menopausal hormone therapy (MHT) or HRT — is the most effective treatment for vasomotor symptoms and has additional benefits for bone health, GSM, and, in early initiators, possibly cardiovascular protection (the “timing hypothesis”).
Types:
- Combined oestrogen-progestogen — for women with a uterus (progestogen protects the endometrium)
- Oestrogen-only — for women after hysterectomy
- Local vaginal oestrogen — low-dose, locally active; for GSM; minimal systemic absorption; does not require progestogen
Routes:
- Transdermal (patch, gel, spray) — preferred for women with elevated thrombosis risk; does not pass through the liver
- Oral — effective but associated with a small increase in VTE risk compared with transdermal preparations
For most healthy women aged under 60, or within 10 years of menopause, benefits typically outweigh risks. Duration should be reviewed periodically. See the Hormone Therapy for Menopause guide for a full risk-benefit breakdown.
Non-Hormonal Options
For women who cannot or choose not to use hormone therapy:
| Option | Evidence | Best For |
|---|---|---|
| SSRIs/SNRIs (e.g., venlafaxine, escitalopram) | Moderate — reduces hot flush frequency 40–60% | Vasomotor symptoms; women with depression |
| Gabapentin / pregabalin | Moderate | Vasomotor symptoms; night sweats |
| Cognitive behavioural therapy (CBT) | Good — reduces distress; improves sleep | Mood, sleep, coping |
| Clonidine | Modest | Hot flushes |
| Fezolinetant (NK3 receptor antagonist) | Strong (new) | Vasomotor symptoms — non-hormonal prescription option |
| Local vaginal oestrogen | Excellent for GSM | GSM (safe even when systemic HRT is not) |
Lifestyle
- Exercise — aerobic and resistance training improve sleep, mood, bone density, and cardiovascular risk
- Diet — adequate calcium (1,200 mg/day postmenopause), vitamin D, and a heart-healthy dietary pattern
- Sleep hygiene — cooling the bedroom, CBT-I for chronic insomnia
- Reducing triggers — hot drinks, alcohol, and spicy food can trigger flushes in some women
- Smoking cessation — smoking is associated with earlier menopause and worse symptoms
Red Flags — When to Seek Prompt Assessment
| Symptom | Why It Matters |
|---|---|
| Postmenopausal bleeding | Must exclude endometrial cancer |
| Intermenstrual bleeding (new or heavy) in perimenopause | May indicate endometrial pathology |
| Sudden severe hot flushes at any age under 40 | May indicate premature ovarian insufficiency |
| New chest pain, palpitations, or breathlessness | Cardiovascular evaluation |
| Severe or rapidly worsening mood symptoms | Depression, not simply perimenopause |
| Urinary symptoms with fever or loin pain | Urinary tract infection or pyelonephritis |
Postmenopausal bleeding — any vaginal bleeding 12 or more months after the last period — always requires prompt medical evaluation, even if it appears minor.
FAQ
Q: At what age does menopause start? The average age of menopause in Australia is 51–52 years. The normal range is roughly 45–55. Menopause before 40 is classified as premature ovarian insufficiency and should be investigated. Natural menopause rarely occurs before 40 without an underlying cause.
Q: Can I get pregnant during perimenopause? Yes. Women remain fertile — though with reduced fertility — throughout perimenopause until 12 months have passed without a period. Contraception is recommended until this point if pregnancy is not desired. Discuss options with your doctor, as some contraceptives also manage perimenopausal symptoms.
Q: Will I know when I’ve hit menopause? Menopause is defined retrospectively: only after 12 consecutive months without a period can you say that the last period was “the menopause.” Many women find this frustrating, particularly when late cycles occur during perimenopause. The symptoms — not the date — are what typically bring women to seek care.
Q: Can lifestyle changes reduce hot flushes? Moderately. Avoiding known triggers (alcohol, hot drinks, spicy food), dressing in layers, and cooling the bedroom at night can reduce flush frequency and severity for some women. Regular aerobic exercise is associated with fewer and less severe vasomotor symptoms in observational studies. For severe symptoms, lifestyle changes alone are usually insufficient; hormone therapy or non-hormonal medications are more effective.
Further Reading
- NICE Clinical Guideline NG23: Menopause — UK national clinical guidance
- Australasian Menopause Society — Consumer Information — Australian evidence-based resources
- The Menopause Society (NAMS) — Position Statements — North American consensus guidance
- Jean Hailes for Women’s Health — Menopause — Plain-language Australian resource
Related Guides
- Women’s Health Hub
- Perimenopause: What to Expect
- Menopause and Sleep: Why Rest Becomes Harder and What Helps
- Hormone Therapy for Menopause: Benefits, Risks, and Who It Suits
- Bone Density and Osteoporosis — What You Need to Know
- Sleep: Why It Matters and What Affects It
- Cardiovascular Risk Assessment — Understanding Your Numbers
- Anxiety: When Worry Becomes a Problem
- Healthy Aging and Longevity Basics
Last updated: May 2026